Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised phase 3 trial




20 Feb 2014

Teriflunomide is an oral disease-modifying therapy approved for treatment of relapsing or relapsing—remitting multiple sclerosis. Aim of the study is to provide further evidence for the safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis.

The Lancet Neurology 2014

Progetti correlati: